Navigation Links
Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
Date:1/15/2014

OXFORD, England and SAN JOSE, California, January 15, 2014 /PRNewswire/ --

Oxford BioTherapeutics, an international biotechnology company developing antibody-drug conjugates for cancer, today announced the appointment of Thomas C Reynolds MD, PhD to its Board of Directors. Dr Reynolds has over 20 years' development experience gained in the biotechnology industry, most recently as Chief Medical Officer at Seattle Genetics.

"I am delighted to welcome Tom at this transformative time for Oxford BioTherapeutics, as the company completes its transition into a fully-fledged oncology product development business," said Bryan Morton, Chairman of Oxford BioTherapeutics. "Dr Reynolds' experience in the oncology field will prove invaluable as we progress our pipeline into the clinic, and in particular his expertise in bringing antibody-drug conjugates to market having led the development and approval of ADCETRIS at Seattle Genetics."

Commenting on his appointment, Thomas C Reynolds MD, PhD, said, "I am highly impressed with Oxford BioTherapeutics' cancer targeting technology, which has continued to mature since my tenure at Seattle Genetics. I am delighted to be able to contribute to the development of the company's exciting antibody-based oncology products."

About Thomas C Reynolds MD, PhD

Dr Reynolds has held a number of senior development roles during his career of over 20 years in the biotechnology industry. Most recently he was Chief Medical Officer at Seattle Genetics, where he had direct oversight of the development and approval of the company's antibody-drug conjugate, ADCETRIS. Prior to this, he was Vice President for Medical Affairs at Zymogenetics, having held the role of Senior Medical Director. Previously, he held a number of senior roles at Targeted Genetics Corporation, culminating in the position of Vice President, Clinical Affairs. He began his industry career at Somatix Therapy Corporation as a Research Scientist. Dr Reynolds gained his MD at Stanford University, where he subsequently conducted postdoctoral research. He also holds a PhD in Biophysics from Stanford University, and a degree in Chemistry from Dartmouth College.

About Oxford BioTherapeutics

Oxford BioTherapeutics is developing a range of antibody-drug conjugates for cancer, based on its OGAP® oncology targeting technology. The OGAP® system incorporates one of the world's largest proprietary proteomic databases, with data on 7,500 cancer cell proteins providing unique, highly-qualified therapeutic targets. The company has established collaborations with leading antibody and cancer toxin technology companies, including Seattle Genetics, to build an in-house pipeline of antibody-drug conjugates (ADCs) against a number of these novel targets. In 2012, Oxford BioTherapeutics entered a strategic agreement to accelerate the development of its ADCs, with partner Menarini providing clinical and manufacturing expertise and investment of up to $1 billion in exchange for commercial rights to the treatments outside the US and Japan.

Oxford BioTherapeutics is based in Oxford, UK and San Jose, CA, and has a strong management team with significant experience of developing antibody-based therapies. The company has completed a number of funding rounds, and is supported by a syndicate of specialist venture capital investors. For more information please visit http://www.oxfordbiotherapeutics.com.

Contacts
Dr Christian Rohlff
CEO
Oxford BioTherapeutics
+44(0)1235-861770
christian.r@oxfordbiotherapeutics.com

David Dible / Sita Shah
Citigate Dewe Rogerson
+44(0)207-638-9571
david.d@citigatedr.co.uk


'/>"/>
SOURCE Oxford BioTherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Oxford University Press to publish BioScience journal starting in 2014
2. Oxford BioMedica Announces Update from ARVO 2013
3. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
4. Oxford Performance Materials and Biomet Microfixation Join Forces
5. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
6. Oxford Finance Completes $271.4 Million Securitization Transaction
7. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
8. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
9. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
10. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
11. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... , ... Rob Lowe is a well recognized television personality, so it seems ... issues that are important to the American public and important to society at large. ... hot topic around the world for a few years. , The climate and how ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Chef Jodi Abel ... scene. Making stops in several cities, she gained a number of delicious recipes ... in Stellenbosch, a town in South Africa’s Western Cape province. It is internationally ...
(Date:2/24/2017)... 2017  Driven by consumers, preference towards more ... fastest growing categories, finds the recently published U.S. ... Care: Multi-regional Market Analysis and Opportunities study ... Kline. "Biotechnology actives are derived from ... effective for skin and hair care applications," explains ...
(Date:2/24/2017)... 24, 2017  VWR Corporation (NASDAQ: VWR), the leading global ... production customers, today reported its financial results for the fourth ... Highlights: 4Q16 record quarterly net sales ... an organic basis. 4Q16 EMEA-APAC ... basis, while the Americas net sales increased 2.5%, or down ...
Breaking Biology Technology:
(Date:2/2/2017)... 2017  EyeLock LLC, a market leader of iris-based ... " What You Should Know About Biometrics in the ... authenticity is a growing concern. In traditional schemes, cryptography ... traditional authentication schemes such as username/password suffer from inherent ... offers an elegant solution to the problem of high-security ...
(Date:1/30/2017)... 2017   Invitae Corporation (NYSE: ... companies, today announced that it will report its fourth ... guidance on Monday, February 13, 2017, and Invitae,s management ... 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... review financial results, guidance, and recent developments and will ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
Breaking Biology News(10 mins):